Long-term methamphetamine-induced decreases of [11C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the Vervet monkey

Synapse

Volumn 35, Issue 4, 2000, Pages 243-249

  Melega, William P ^a   Laćan, Goran ^a   Desalles, Antonio A F ^a   Phelps, Michael E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dopamine transporter; Monkey; Neuroprotection; Neurotoxicity; Positron emission tomography

Indexed keywords

ATROPINE; COCAINE DERIVATIVE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; KETAMINE; METHAMPHETAMINE; MIDAZOLAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CALCULATION; CAUDATE NUCLEUS; DOPAMINERGIC SYSTEM; DOSE RESPONSE; MALE; MONKEY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN;

ANIMALS; CARBON RADIOISOTOPES; CARRIER PROTEINS; CAUDATE NUCLEUS; CERCOPITHECUS AETHIOPS; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROTOXINS; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0343114278     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(20000315)35:4<243::AID-SYN1>3.0.CO;2-N     Document Type: Article

References (46)

1. Bjorklund A, Rosenblad C, Winkler C, Kirik D. 1997. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 4:186-200.
2. Bowyer JF, Holson RR. 1995. Methamphetamine and amphetamine neurotoxicity. In: Chang LW, Dyers RS, editors. Handbook of neurotoxicology, vol 2. New York: Marcel Dekker. p 845-870.
3. Cadet JL, Brannock C. 1998. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 32:117-131.
4. Cass W. 1996. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J Neurosci 16:8132-8139.
5. Cass WA. 1997. Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. J Pharmacol Exp Ther 280:105-113.
6. Chao CC, Lee EHL. 1998. Alterations in antioxidant enzyme systems and behavior in rats by intrastriatal injection of glial cell line-derived neurotrophic factor. Soc Neurosci Abstr 24:42.
7. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34:423-431.
8. Fuller R. 1992. Comparison of MPTP and amphetamines as dopaminergic neurotoxins. Ann NY Acad Sci 648:87-95.
9. Gash D, Zhang Z, Cass W, Ovadia A, Simmerman L, Martin D, Russell D, Collins F, Hoffer B, Gerhardt G. 1995. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J Comp Neurol 363:345-358.
10. Gash D, Zhimming Z, Ovadia A, Cass W, Simmerman A, Russell D, Martin D, Lapchak P, Collins F. 1996. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255.
11. Gash DM, Zhang Z, Gerhardt G. 1998. Neuroprotective and neurorestorative properties of GDNF. Am Neurolog Assoc 44 (Suppl 1):S121-S125.
12. Giros B, Jaber M, Jones S, Wightma R, Caron M. 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
13. Granholm A-C, Srivastava N, Mott JL, Henry S, Henry M, Westphal H, Pichel JG, Shen L, Hoffer B. 1997. Morphological alterations in the peripheral and central nervous systems of mice lacking glial cell line-derived neurotrophic factor (GDNF): Immunohistological studies. J Neurosci 17:1168-1178.
14. 11C]-CFT and PET in a primate model of parkinsonism. NeuroReport 3:265-268.
15. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. 1998. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979-1986
16. 3H]CFT. Synapse 9:177-187.
17. Kearns C, Gash D. 1995. GDNF protects nigral dopamine neurons against 6-hydoxydopamine in vivo. Brain Res 672:104-111.
18. Kroll R, Pagel M, Muldoon L, Roman-Goldstein S, Neuwelt E. 1996. Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 38:746-754.
19. Kuczenski R, Segal D, Cho A, Melega W. 1995. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15:1308-1317.
20. Lapchak P, Miller P, Jiao S, Araujo D, Hilt D, Collins F. 1996a. Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. NeuroGen 5:197-205.
21. Lapchak PA, Jiao S, Miller PJ, Williams LR, Cummins V, Inouye G, Matheson CR, Yan Q. 1996b. Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Cell Tissue Res 286:179-189.
22. Lapchak P, Martin D, Jiao S, Miller P, Hilt D. 1997a. Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Exp Neurol 144:29-34.
23. Lapchak P, Gash D, Collins F, Hilt D, Araujo D. 1997b. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Exp Neurol 145:309-321.
24. Lin L-F, Doherty DH, Lile JD, Bektesh S, Collins F. 1993. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
25. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [C-11]WIN-35,428. J Neurosci 18:8417-8422.
26. 18F]Fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys. Exp Neurol 141:318-329.
27. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang S-C, Phelps ME. 1997. Recovery of striatal dopamine function after acute amphetamine and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 766:113-120.
28. 11C]WIN 35,428-positron emission tomography studies. Neurosci Lett 258: 17-20.
29. Meltzer PC, Liang AY, Brownell A-L, Elmaleh DR, Madras BK. 1993. Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J Med Chem 36:855-862.
30. Moore MW, Klein RD, Farinas I, Sauer H, Armanini M, Phillips H. Reichardt LF,Ryan AM, Carver-Moore K, Rosenthal A. 1996. Renal and neuronal abnormalities in mice lacking GDNF. Nature 382:76-79.
31. Olanow C. 1990. Oxidation reactions in Parkinson's disease. Neurology 40:32-37.
32. Patlak CS, Blasberg RG. 1985. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5:584-590.
33. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY. 1982. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235:93-103.
34. Rosenblad C, Martinez-Serrano A, Bjorklund A. 1998. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's Disease. Neuroscience 82:129-137.
35. Sauer H, Rosenblad C, Bjorklund A. 1995. Glial cell line-derived neurotrophic factor but not transforming growth factor b3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA 92:8935-8939.
36. 3/KF. Appl Radiat Isot 46:893-897.
37. Seiden LS, Fischman MW, Schuster CR. 1976. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1:215-219.
38. Seiden LS, Sabol KE, Ricaurte GA. 1993. Amphetamine: effects on catecholamine systems and behavior. Ann Rev Pharmacol Toxicol 33:639-77.
39. Sheng P, Wang X, Landenheim B, Epstein C, Cadet J. 1996. AP-1 DNA-binding activation by methamphetamine involves oxidative stress. Synapse 24:213-217.
40. Solberg T, De Salles A, Hovda D, Holly F. 1994. A universal, multi-modality localization system for animal radiosurgery. Acta Neurochir Suppl 62:28-32.
41. 3H]GBR 12935 as markers of dopamine innervation density in brain. Synapse 25:163-175.
42. Tomac A, Lindquist E, Lin L-FH, Ogren SO, Young D, Hoffer BJ, Olson L. 1995. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339.
43. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18:419-427.
44. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med 2:699-703.
45. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS. 1989. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 486:73-78.
46. Zhang Z, Miyoshi Y, Lapchak PA, Collins F, Hilt D, Lebel C, Kryscio R, Gash DM. 1997. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 282:1396-1401.